FDA.reportPublic FDA data

denosumab-nxxp 120 MG in 1.7 ML Injection

RxCUI
2723338
RxNorm name
denosumab-nxxp 120 MG in 1.7 ML Injection
Display name
denosumab-nxxp 120 MG in 1.7 ML Injection
Full name
denosumab-nxxp 120 MG in 1.7 ML Injection
Term type
PSN
Status
DailyMed mapping
Updated
2026-06-04 23:39:16

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
761444Bildyosdenosumab-nxxp351(k) InterchangeableRx2026-07-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
b1f0590e-f5bb-44ac-99a0-4aa4596c7e54denosumab-nxxp 120 MG in 1.7 ML Injection [PSN] · 1.7 ML denosumab-nxxp 70 MG/ML Injection [SCD] · denosumab-nxxp 120 MG per 1.7 ML Injection [SY]32These highlights do not include all the information needed to use BILPREVDA safely and effectively. See full prescribing information for BILPREVDA. BILPREVDA ® (denosumab-nxxp) injection, for subcutaneous use Initial U.S. Approval: 2025 BILPREVDA ® (denosumab-nxxp) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differen20250910